• Global Clinical Research & Health Data Analytics Company
  • The MMS Difference
    • About Us
    • Leadership
    • Certifications
  • Services
    • Regulatory Affairs and Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Drug Safety and Pharmacovigilance
    • Compliance and Transparency
    • Data Sciences
  • Working with MMS
  • News and Media
  • Webinars
  • MMS Blog
  • Careers
  • Contact Us
MMS Holdings
Whitepaper: Six Changes that Pharmaceutical Companies Should Consider in Response to COVID-19

Whitepaper: Six Changes that Pharmaceutical Companies Should Consider in Response to COVID-19

by Don McLean | Apr 8, 2020 | Blog

Whitepaper: Six Changes that Pharmaceutical Companies Should Consider in Response to COVID-19 [Fill out the form below to access the whitepaper] In the wake of the global pandemic of COVID-19, also known and SARS-COV-2, regulators, health authorities, and lawmakers...
Part 2: The Case for Better Health History Records – How Much History is Needed and How Should it be Reviewed?

Part 2: The Case for Better Health History Records – How Much History is Needed and How Should it be Reviewed?

by Don McLean | Feb 21, 2019 | Blog

Part 2: The Case for Better Health History Records – How Much History is Needed and How Should it be Reviewed? by Barbara Rusin Part 1 of this medical histories series focused on the regulations relevant to clinical trial subject eligibility, and the possible issues...
Part 1: The Case for Better Health History Records – Regulatory Requirements

Part 1: The Case for Better Health History Records – Regulatory Requirements

by Don McLean | Aug 9, 2018 | Blog

Part 1: The Case for Better Health History Records – Regulatory Requirements by Barbara Rusin It is evident that during numerous audits, while working for the FDA and at MMS, clinical investigators are enrolling ineligible study subjects. A few of the ineligible...

Recent Posts

  • Modernizing the Functional Service Provider (FSP) Relationship: Innovations to bring value beyond “Global and Scalable”
  • EY Announces Dr. Uma Sharma of MMS Holdings as an Entrepreneur Of The Year® 2020 Michigan and Northwest Ohio Award Finalist
  • MichBio Invites MMS Founder and Chief Scientific Officer Dr. Uma Sharma to Join Board of Directors
  • How Zero Contact GXP Audits Ensure Compliance While Protecting Auditors and Auditees during the Global Pandemic
  • FDA Orphan Drug Designation Applications Whitepaper

Tags

ALZ awareness Alzheimers biosimilars biostatistics Clinical Development clinical research clinical study reports clinical trials clinical trial transparency Community Compliance COVID-19 CRO data management data privacy data science drug development EMA ENDALZ FDA Flint GDPR GXP auditing Health Analytics Collective Health Canada Lay summaries leadership medical writing NDA submission opioids pharma pharmacovigilance PhUSE Policy 0070 quality control rare disease real world data regulatory operations REMS resourcing statistical programming suicidality transparency trial regulation Volunteering